Vor Biopharma, Inc. (VOR)
22.71
-0.65
(-2.78%)
USD |
NASDAQ |
Aug 24, 16:00
22.71
0.00 (0.00%)
After-Hours: 20:00
Vor Biopharma Enterprise Value : 773.44M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 773.44M |
| August 21, 2026 | 808.84M |
| August 20, 2026 | 792.77M |
| August 19, 2026 | 820.82M |
| August 18, 2026 | 804.48M |
| August 17, 2026 | 789.78M |
| August 14, 2026 | 790.87M |
| August 13, 2026 | 805.02M |
| August 12, 2026 | 753.29M |
| August 11, 2026 | 821.36M |
| August 10, 2026 | 809.38M |
| August 07, 2026 | 825.72M |
| August 06, 2026 | 827.35M |
| August 05, 2026 | 749.48M |
| August 04, 2026 | 748.39M |
| August 03, 2026 | 702.65M |
| July 31, 2026 | 688.49M |
| July 30, 2026 | 723.88M |
| July 29, 2026 | 601.36M |
| July 28, 2026 | 625.86M |
| July 27, 2026 | 595.37M |
| July 24, 2026 | 585.57M |
| July 23, 2026 | 570.32M |
| July 22, 2026 | 599.18M |
| July 21, 2026 | 628.59M |
| Date | Value |
|---|---|
| July 20, 2026 | 487.00M |
| July 17, 2026 | 521.85M |
| July 16, 2026 | 481.01M |
| July 15, 2026 | 521.31M |
| July 14, 2026 | 544.18M |
| July 13, 2026 | 518.59M |
| July 10, 2026 | 579.03M |
| July 09, 2026 | 612.25M |
| July 08, 2026 | 642.75M |
| July 07, 2026 | 631.31M |
| July 06, 2026 | 631.31M |
| July 02, 2026 | 657.99M |
| July 01, 2026 | 538.19M |
| June 30, 2026 | 539.28M |
| June 29, 2026 | 519.27M |
| June 26, 2026 | 383.80M |
| June 25, 2026 | 320.40M |
| June 24, 2026 | 296.02M |
| June 23, 2026 | 316.07M |
| June 22, 2026 | 320.95M |
| June 18, 2026 | 296.56M |
| June 17, 2026 | 325.28M |
| June 16, 2026 | 275.97M |
| June 15, 2026 | 273.81M |
| June 12, 2026 | 289.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Dyne Therapeutics, Inc. | 3.641B |
| Agenus, Inc. | 591.52M |
| Amgen, Inc. | 283.25B |
| Anika Therapeutics, Inc. | 272.43M |
| BioCryst Pharmaceuticals, Inc. | 2.955B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.81M |
| Total Expenses (Quarterly) | 62.81M |
| EPS Diluted (Quarterly) | -1.157 |
| Earnings Yield | -367.2% |
| Normalized Earnings Yield | -127.76 |